Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Abstract 2961: AZD9592, an EGFR/cMET bispecific antibody-drug conjugate ...
Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate ...
(PDF) Abstract A109: AZD9291: an irreversible, potent and selective ...
Pagina 38 | Abstract Behang voor je muur ️ Kies uit 3500+ ontwerpen
Medical Abstract Example at Todd Reno blog
tilatamig samrotecan (AZD9592) / AstraZeneca
【AACR 2023】ADC药物”角力”AACR-公司新闻-北京百普赛斯生物科技股份有限公司
阿斯利康的双抗ADC药物在华申请临床获受理（附双抗ADC汇总）_治疗_研究_肿瘤
Frontiers | Identifying optimal tumor-associated antigen combinations ...
A Comprehensive Introduction to Bispecific ADCs | AxisPharm
AACR2023| ADC药物及可用临床前动物模型 - 知乎
Expanding new trends and technologies in ADC therapeutics
阿斯利康双抗（EGFRxcMET)ADC有何启示医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
强生EGFR/c-MET双抗两项III期成功，隐忧难解，阿斯利康ADC能否逆袭 - 知乎
ADC新药“大闹”AACR医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
阿斯利康：自研 ADC 开始蓄势，3 款新药联袂亮相 | AACR2023_截图_肿瘤_来自
Phase Ib study of afatinib plus standard-dose cetuximab in patients ...
The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB ...
【AACR 2023】ADC药物”角力”AACR - 自主发布 - 资讯 - 生物在线
阿斯利康EGFR/c-Met ADC在华申报临床 3月9日，据CDE官网公示， 阿斯利康 ADC药物AZD9592在华申报临床。AZD9592 ...
药明系高管创立，双抗ADC黑马藏不住了_医药_李竞_博士
2023AACR | ADC药物一览，多款双抗ADC亮相，恒瑞、石药、Seagen众星云集 2023年第114届美国癌症研究协会年会(AACR ...
双抗ADC：1+1>2 点击上方的 行舟Drug 添加关注 前言 抗体偶联药物（ADC）包括抗体、连接子和细胞毒性有效载荷。与传统化疗相比 ...
ISSX 2022 - Hypha Discovery
双抗ADC全球在研格局 - 知乎
刚刚！阿斯利康三款药物获批临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
阿斯利康最新财报：只用3天发现173款高质量抗体！肝癌CAR-T疗法的首个临床结果… 今日， 阿斯利康 （AstraZeneca）公司公布了 ...
阿斯利康也“Follow”第一三共
In vivo antitumor efficacy of AZD9291 in subcutaneous xenograft models ...
双抗ADC全球在研格局 ADC药物在过去十多年间已取得了长足的进展，自2000年第一款药物Mylotarg上市，ADC已历经了三代。截止目前 ...
Frontiers | A narrative review of antibody–drug conjugates in EGFR ...
Combination of T cell-redirecting bispecific antibody ERY974 and ...
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC ...
阿斯利康EGFR/C-Met双靶点ADC——AZD9592专利公开，EGFR端亲和力高低成为重要考量因素医药新闻-ByDrug-一站式医药资源 ...
P1.12-04 In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a ...
AZD9496 demonstrates superior antitumor effects on ER-mutant expressing ...
医药魔方
Frontiers | Targeting tumor-associated macrophages with STING agonism ...
How does AstraZeneca's PARP inhibitor differentiate?
EGFR敏感突变肺癌新药临床试验：EGFR/c-Met双靶点ADC药物AZD9592-印塔健康官网
AZD9291 inhibits tumor growth in xenograft models through degradation ...
AZD9291 binding mode and structure. | Download Scientific Diagram
Acquired resistance to AZD9291 as an upfront treatment is dependent on ...
阿斯利康 2022Q3 中国区收入 15.41 亿美元，再涨 8%！管线进展亮点频现
The combination of AZD9291 with a MEK inhibitor effectively inhibits ...
Tilatamig samrotecan (AZD9592) | ADC | MedChemExpress
强生EGFR/c-Met双抗在中国申报皮下注射新剂型-试药员招聘与临床试验信息平台
AZD-9592 - Drug Targets, Indications, Patents - Synapse
Aurora kinase B inhibitor AZD1152: repurposing for treatment of lupus ...
AZD9291 inhibits GBM tumorigenesis in vivo. a Mice bearing U87 ...
制药巨头2024年展望：值得期待的里程碑事件
AZD9291 inhibits EGFR phosphorylation and downstream signaling in ...
强生EGFR/c-MET双抗两项III期成功，隐忧难解，阿斯利康ADC能否逆袭 EGFR/c-MET双抗组合疗法二线治疗NSCLC III期 ...
(PDF) ASO Visual Abstract: Impact of Quilting Sutures on Surgical ...
Expression of AXL and sensitivity to AZD9291 in non-small-cell lung ...
(PDF) Acquired resistance to AZD9291 as an upfront treatment is ...
JNJ-61186372 in combination with AZD9291 was effective and durable in ...
Effect of high dose-AZD9291 treatment after acquisition of EGFR-TKI ...
(PDF) Discovery and characterization of AZD9272 and AZD6538—Two novel ...
双抗ADC靶点介绍及在研药物研究进展-缔码生物
Structural Basis of AZD9291 Selectivity for EGFR T790M | Journal of ...
In Vivo Anticancer Activity of AZD3965: A Systematic Review
AZD9291 (Osimertinib) (Osimertinib; Mereletinib) | CAS 1421373-65-0 ...
AZD9829 / AstraZeneca
技术前沿 | 双抗ADC的CMC工艺开发挑战与解决方案 #万物偶联 抗体偶联药物（Antibody-Drug Conjugate, ADC ...
AZD9291 treatment is effective in erlotinib-resistant cells and induces ...
Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the ...
The third-generation EGFR inhibitor AZD9291 overcomes primary ...
从EGFR选择性看百利天恒双抗ADC|NSCLC|EGFR|HER3|ADC|ORR|抗体|靶点|-健康界
不超50亿！翰森进军双抗ADC，扩大与普米斯EGFR / cMet双抗合作 的欢迎关注 凯莱英 药闻2024年3月14日， 翰森制药 与普米斯 ...
Discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 ...
High efficacy of third generation EGFR inhibitor AZD9291 in a ...
阿斯利康FRα ADC在华申报临床 8月25日，CDE官方显示， 阿斯利康 提交AZD5335的临床试验获得受理。AZD5335 是由FRα ...
Effect of AZD8542 in an orthotopic model of pancreatic cancer with ...
魔法子弹——ADC药物进化史 - 知乎
Molecular characterization and cytotoxic effects of AZD5363, AZD8542 ...
23 ESMO丨EGFR/cMET双抗研究梳理，国内申报上市 无论是FDA还是CDE，对于双抗行业的发展都做了一系列的指导原则公布，如果可以用 ...
AZD9291 inhibits EGFR downstream signaling pathways and induces ...
Clin Cancer Res：AZD9291联合MEK抑制剂克服包含C797S的获得性耐药-MedSci.cn
(PDF) AZD9291-induced Acute Interstitial Lung Disease
ADCdb: the database of antibody-drug conjugates
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is ...
普方生物丨不只FRα ADC，更在于EGFR/cMetADC ——快 讯——近期，被 Genmab 18亿美金全现金收购普方生物引起行业关注 ...
2023AACR | ADC药物一览，多款双抗ADC亮相，恒瑞、石药、Seagen众星云集_Her_临床_生物
AZD9291 enhances ubiquitination and proteosomal degradation of ...
Acquired resistance to AZD9291 as first-line treatment is mediated by ...
ATM inhibitors: AZD0156 was modified to AZD1390, an orally available ...
Proof-of-concept clinical studies validating AZD9291 as a... | Download ...
Mechanisms of Acquired Resistance to AZD9291 - Journal of Thoracic Oncology
(PDF) Preclinical Characterization of AZD5305, A Next-Generation ...
